|Bid||60.52 x 3000|
|Ask||62.02 x 800|
|Day's Range||61.22 - 62.10|
|52 Week Range||52.83 - 66.41|
|PE Ratio (TTM)||107.69|
|Earnings Date||Jul 27, 2018|
|Forward Dividend & Yield||1.92 (3.07%)|
|1y Target Est||69.02|
Dividend reinvestment is an amazingly powerful investment strategy. In fact, studies have shown that over a 20-year holding period, dividends account for 60% of all the gains in the S&P 500! Think about this for a minute. Since 1998, the S&P 500 would be around 60% lower if not for the benefits attributed to dividends.
Affimed NV (NASDAQ: AFMD ) shares were tumbling Friday after the release of updated data on its Hodgkin lymphoma treatment candidate. The metric investors are reacting to may be a decline in complete metabolic ...
Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.
Merck & Co Inc. (NYSE:MRK) is currently trading at a trailing P/E of 107.7x, which is higher than the industry average of 23.5x. Although some investors may jump to theRead More...
In spite of a strong start in 2018, the pharma/biotech industry is struggling currently, presumably due to a shift in focus to lowering of high drug prices and faster approval of generics. This has led to an increase in merger & acquisition activity and may boost innovation and capital building in the biotech industry. Earlier in the year, we have seen Sanofi SA (NYSE:SNY) and Celgene Corporation (NASDAQ:CELG) acquiring smaller biotech companies.
Merck's (MRK) Keytruda gets FDA approval for primary mediastinal B-cell lymphoma (PMBCL) - its second label expansion approval this week.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 13) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...
Medical tourism has been a great business for Manna Wang, an insurance agent in Shenzhen who’s been helping Chinese women travel to Hong Kong for a vaccine against the human papillomavirus, or HPV, which can cause cervical cancer. In the two years since Merck & Co.’s Gardasil 9 became available in Hong Kong, about 2 million mainlanders have come for the shots, according to the Xinhua News Agency. With the drugmaker unable to keep up, some clinics are turning away Chinese patients, and angry mainlanders have protested at Merck’s local office.
Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA®, the company’s anti-PD-1 therapy, for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma , or who have relapsed after two or more prior lines of therapy.
Merck (MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) for GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant), the company’s 9-valent HPV vaccine. The application is seeking approval for an expanded age indication for GARDASIL 9 for use in women and men ages 27 to 45 for the prevention of certain cancers and diseases caused by the nine human papillomavirus (HPV) types covered by the vaccine. “Women and men ages 27 to 45 continue to be at risk for acquiring HPV, which can lead to cervical cancer and certain other HPV-related cancers and diseases,” said Dr. Alain Luxembourg, director, clinical research, Merck Research Laboratories.
Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA®, the company’s anti-PD-1 therapy, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 as determined by an FDA-approved test.
Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing two late-stage studies on their Alzheimer's disease candidate, lanabecestat.
The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.
After small-caps took charge of the bull run through February to May, mega caps returned to the forefront in June. This is especially true as the blue-chip Dow Jones index climbed 3.7% to start June, outpacing the gains of 2.7% for the S&P 500 and 2.4% for the Russell 2000. Notably, the Dow Jones surged 2.8% last week, its biggest weekly gain since March.Source: Pixabay
The alliance of nearly 500 chief executives reports a successful first year in addressing inclusion at their firms and has big goals ahead.
Walking around the convention floor at BIO was a remarkable experience this week in Boston. Not only were there an endless number of human health companies present, there were also animal health companies. States like Georgia, New Jersey, Maryland, Hawaii were also present, and countries too, among them Estonia, Japan, Switzerland, and Canada was a major sponsor of this year’s conference. The message at BIO was clear: The world needs biotech.
The Zacks Analyst Blog Highlights: Merck, Occidental Petroleum, Capital One Financial, Kimberly-Clark and Allstate